Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A
The purpose of this study is to evaluate the efficacy of GSK Biologicals' vaccine GSK1437173A in the prevention of Herpes zoster (HZ) in autologous haematopoietic cell transplant recipients 18 years of age and older. To this end, the study will evaluate vaccine efficacy (VE) of the GSK1437173A vaccine, administered on a 2-dose schedule, compared to placebo in reducing the risk of developing HZ in this population.
Inclusion Criteria:
Study entry (enrollment) occurs at the Pre-vaccination visit.
OR Female subjects of childbearing potential may be enrolled in the study, if the subject has practiced adequate contraception for 30 days prior to vaccination with the study vaccine/placebo, and has a negative pregnancy test on the day of vaccination, and has agreed to continue adequate contraception during the entire treatment period and for 12 months after completion of the vaccination series (i.e., until Month 13).
Exclusion Criteria:
Hafia, 31096, Israel
Gunma, 377-0280, Japan
St'Petersburg, 191024, Russia
Moreleta Park, Pretoria, 0001, South Africa
Jellanamdo, 519-809, South Korea
Kyunggi-do, 410-769, South Korea
Badalona/Barcelona, 08916, Spain
Pozuelo de Alarcón/Madrid, 28223, Spain
Taoyuan Hsien, 333, Taiwan
Headington, Oxford, OX3 7LE, United Kingdom